Patrick M. Leimgruber – General Manager, UPSA
Patrick Leimgruber of UPSA discusses the company’s strategic growth roadmap and ambitions to expand its product portfolio and reach EUR 1 billion in net sales by 2027. He also outlines…
Understanding the mechanisms of disease
The Friedrich Miescher Institute is devoted to fundamental biomedical research aimed at understanding the basic molecular mechanisms of health and disease. We communicate and patent our findings to enable their translation into medical application.
The FMI focuses on the fields of
» Epigenetics
» Quantitative Biology
» Neurobiology
In these fields, the FMI has gained international recognition as a center of excellence in innovative biomedical research.
Training young scientists
The Friedrich Miescher Institute contributes to the training of graduate students and postdoctoral fellows. Through its PhD program, which was established as early as 1970, the FMI attracts top international students. The FMI is affiliated with the University of Basel, where most of the graduate students are enrolled and where it contributes to the teaching program. Many FMI alumni have gone on to pursue successful careers in Novartis, in other pharmaceutical companies, or in academic research.
Contact
Friedrich Miescher Institute for Biomedical Research
Maulbeerstrasse 66
4058 Basel
Switzerland
Tel.: +41 61 697 66 51
Patrick Leimgruber of UPSA discusses the company’s strategic growth roadmap and ambitions to expand its product portfolio and reach EUR 1 billion in net sales by 2027. He also outlines…
Founded in 2020 with a focus on diseases related to skeletal muscle damage, MUVON Therapeutics is currently targeting a significant unmet need in women’s health, Female Stress Urinary Incontinence (SUI).…
Lars Nieba PhD, CEO of Engimmune, shares insights into the company’s innovative approach to T-cell therapies and its strategic direction as it prepares for its Series A funding round. Nieba…
Myriam DeLeone, General Manager of Amgen Switzerland, discusses the company’s commitment to tackling diseases prevalent in Switzerland such cardiovascular diseases and osteoporosis, Amgen’s expanding biosimilars profile, and how the company is…
Raimund Bruhin discusses Swissmedic’s participation in cross-border regulatory initiatives such as the Access Consortium and Orbis and its efforts to support the Global South in developing regulatory standards. Bruhin also…
Adrian Hunn of Swiss Medtech, shares insights into his role and the future of Switzerland’s medtech sector. He discusses the association’s focus on fostering innovation, navigating regulatory challenges, and promoting…
David Veitch, the CEO of Basilea Pharmaceutica, shares his insights into the company’s strategic vision to become a global leader in the antifungal and antibacterial space. Veitch discusses the unique…
Dimitri Gitas, Managing Director of MSD Switzerland, discusses the strategic importance of Switzerland, not only as a management hub for the company, but as a manufacturing location and clinical research…
Stefan Berg, General Manager of Pharmaplan AG, offers insight into the company’s transformative journey as it becomes part of Exyte Group, a global leader in advanced engineering. Berg discusses Pharmaplan’s…
David Traub, General Manager of Novartis in its home country of Switzerland, reflects on his journey to Novartis, emphasizing the need for innovation in Swiss healthcare. He discusses challenges in…
Miro Venturi, Executive Chairman at Stragen, explores the company’s strategic focus on addressing critical healthcare challenges, particularly drug shortages, while emphasizing its commitment to expanding its product portfolio in critical…
Dr Daniel Roth outlines his long-standing career with Menarini Group, its strategic evolution in Switzerland, and the broader challenges facing the healthcare industry. Dr Roth emphasizes the importance of building…
See our Cookie Privacy Policy Here
